Barclays’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $31.9M | Sell |
525,400
-1,796,600
| -77% | -$105M | 0.01% | 904 |
|
|
2025
Q4 | $125M | Buy |
2,322,000
+2,009,900
| +644% | +$96.7M | 0.03% | 410 |
|
|
2025
Q3 | $14.1M | Sell |
312,100
-1,768,000
| -85% | -$82.6M | ﹤0.01% | 1427 |
|
|
2025
Q2 | $96.3M | Buy |
+2,080,100
| New | +$102M | 0.02% | 479 |
|
|
2025
Q1 | – | Sell |
-116,900
| Closed | -$6.61M | – | 5281 |
|
|
2024
Q4 | $6.61M | Sell |
116,900
-1,900
| -2% | -$106K | ﹤0.01% | 1911 |
|
|
2024
Q3 | $6.15M | Buy |
+118,800
| New | +$5.57M | ﹤0.01% | 1903 |
|
|
2024
Q2 | – | Sell |
-38,800
| Closed | -$2.1M | – | 4897 |
|
|
2024
Q1 | $2.1M | Buy |
+38,800
| New | +$1.98M | ﹤0.01% | 2525 |
|
|
2023
Q3 | – | Sell |
-474,600
| Closed | -$30.4M | – | 4604 |
|
|
2023
Q2 | $30.4M | Buy |
474,600
+321,000
| +209% | +$21.5M | 0.02% | 600 |
|
|
2023
Q1 | $10.6M | Sell |
153,600
-335,000
| -69% | -$23.6M | ﹤0.01% | 1130 |
|
|
2022
Q4 | $35.2M | Buy |
+488,600
| New | +$36.8M | 0.02% | 636 |
|
|
2022
Q1 | – | Sell |
-242,900
| Closed | -$15.1M | – | 4977 |
|
|
2021
Q4 | $15.1M | Buy |
242,900
+136,600
| +129% | +$8.01M | 0.01% | 1063 |
|
|
2021
Q3 | $6.29M | Buy |
106,300
+100,000
| +1,587% | +$6.59M | ﹤0.01% | 1476 |
|
|
2021
Q2 | $421K | Hold |
6,300
| – | – | ﹤0.01% | 3167 |
|
|
2021
Q1 | $398K | Sell |
6,300
-417,000
| -99% | -$25.9M | ﹤0.01% | 3316 |
|
|
2020
Q4 | $26.3M | Buy |
423,300
+152,300
| +56% | +$9.36M | 0.01% | 716 |
|
|
2020
Q3 | $16.3M | Sell |
271,000
-1,021,000
| -79% | -$61.5M | 0.01% | 833 |
|
|
2020
Q2 | $76M | Buy |
1,292,000
+712,900
| +123% | +$42.6M | 0.06% | 242 |
|
|
2020
Q1 | $32.3M | Sell |
579,100
-24,559,800
| -98% | -$1.5B | 0.03% | 453 |
|
|
2019
Q4 | $1.61B | Buy |
25,138,900
+24,443,900
| +3,517% | +$1.4B | 0.9% | 13 |
|
|
2019
Q3 | $35.2M | Sell |
695,000
-421,300
| -38% | -$19.8M | 0.02% | 590 |
|
|
2019
Q2 | $50.6M | Sell |
1,116,300
-1,029,300
| -48% | -$47.9M | 0.03% | 484 |
|
|
2019
Q1 | $102M | Buy |
2,145,600
+1,644,400
| +328% | +$81.9M | 0.07% | 227 |
|
|
2018
Q4 | $26.1M | Sell |
501,200
-2,300
| -0.5% | -$124K | 0.02% | 629 |
|
|
2018
Q3 | $31.3M | Sell |
503,500
-267,100
| -35% | -$15.9M | 0.02% | 630 |
|
|
2018
Q2 | $42.6M | Sell |
770,600
-733,400
| -49% | -$39.6M | 0.04% | 419 |
|
|
2018
Q1 | $95.1M | Buy |
1,504,000
+908,000
| +152% | +$58.4M | 0.07% | 228 |
|
|
2017
Q4 | $36.5M | Sell |
596,000
-10,300
| -2% | -$644K | 0.03% | 528 |
|
|
2017
Q3 | $38.6M | Sell |
606,300
-184,600
| -23% | -$10.8M | 0.04% | 403 |
|
|
2017
Q2 | $44.1M | Buy |
790,900
+208,300
| +36% | +$11.3M | 0.05% | 313 |
|
|
2017
Q1 | $31.7M | Sell |
582,600
-41,300
| -7% | -$2.27M | 0.03% | 383 |
|
|
2016
Q4 | $36.5M | Sell |
623,900
-168,600
| -21% | -$9.22M | 0.04% | 355 |
|
|
2016
Q3 | $42.7M | Buy |
792,500
+701,900
| +775% | +$45.1M | 0.05% | 294 |
|
|
2016
Q2 | $6.66M | Sell |
90,600
-133,000
| -59% | -$9.4M | 0.01% | 1109 |
|
|
2016
Q1 | $14.1M | Sell |
223,600
-1,285,000
| -85% | -$81M | 0.02% | 614 |
|
|
2015
Q4 | $103M | Buy |
1,508,600
+24,300
| +2% | +$1.61M | 0.12% | 144 |
|
|
2015
Q3 | $87.6M | Buy |
1,484,300
+50,200
| +4% | +$3.18M | 0.11% | 166 |
|
|
2015
Q2 | $94.7M | Buy |
1,434,100
+54,600
| +4% | +$3.6M | 0.11% | 153 |
|
|
2015
Q1 | $88.3M | Sell |
1,379,500
-699,900
| -34% | -$43.8M | 0.1% | 182 |
|
|
2014
Q4 | $123M | Buy |
2,079,400
+971,200
| +88% | +$54.8M | 0.12% | 138 |
|
|
2014
Q3 | $56.5M | Buy |
1,108,200
+465,800
| +73% | +$23.3M | 0.05% | 289 |
|
|
2014
Q2 | $30.8M | Sell |
642,400
-2,129,100
| -77% | -$105M | 0.03% | 486 |
|
|
2014
Q1 | $141M | Buy |
2,771,500
+2,461,400
| +794% | +$131M | 0.16% | 99 |
|
|
2013
Q4 | $16.4M | Sell |
310,100
-21,800
| -7% | -$1.11M | 0.02% | 885 |
|
|
2013
Q3 | $15.3M | Sell |
331,900
-250,300
| -43% | -$11M | 0.02% | 841 |
|
|
2013
Q2 | $26M | Buy |
+582,200
| New | +$25.3M | 0.03% | 509 |
|
Other funds holding BMY
VCM
VPM
Barclays's BMY Position: Q1 2026 in Review
Barclays reduced its Bristol-Myers Squibb (BMY) stake by 26% in Q1 2026, selling an estimated $111M and leaving 5,419,207 shares worth $329M. The position accounts for 0.08% of the portfolio, ranked #189.
Barclays first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $511M in Q1 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Barclays held 5,419,207 shares of Bristol-Myers Squibb worth $329M as of Q1 2026.
- Barclays sold 1,899,064 Bristol-Myers Squibb shares in Q1 2026, an estimated $111M.
- Bristol-Myers Squibb made up 0.08% of Barclays's portfolio in Q1 2026, its #189 holding.
- Barclays first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
- Barclays's Bristol-Myers Squibb position peaked at $511M in Q1 2025.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.